Shin Nippon Biomedical Laboratories, Ltd. Share Price Deutsche Boerse AG
Equities
YB3
JP3379950003
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8 EUR | +3.23% | +3.23% | -23.81% |
Sales 2024 | 26.45B 168M 155M 13.19B | Sales 2025 * | 30.5B 194M 179M 15.21B | Capitalization | 58.49B 372M 343M 29.16B |
---|---|---|---|---|---|
Net income 2024 | 5.53B 35.17M 32.42M 2.76B | Net income 2025 * | 4.3B 27.34M 25.2M 2.14B | EV / Sales 2024 | 2.39 x |
Net Debt 2024 * | 19.51B 124M 114M 9.73B | Net Debt 2025 * | 22.77B 145M 133M 11.35B | EV / Sales 2025 * | 2.66 x |
P/E ratio 2024 |
11.4
x | P/E ratio 2025 * |
13.6
x | Employees | 1,341 |
Yield 2024 |
3.29% | Yield 2025 * |
3.56% | Free-Float | 48.8% |
1 day | +3.23% | ||
1 week | +3.23% | ||
Current month | -10.61% | ||
1 month | -8.57% | ||
3 months | -20.00% | ||
6 months | -18.78% | ||
Current year | -23.81% |
Managers | Title | Age | Since |
---|---|---|---|
Ryoichi Nagata
CEO | Chief Executive Officer | 65 | 31/08/81 |
Shinji Nitanda
DFI | Director of Finance/CFO | 55 | 30/04/02 |
Terumasa Hirai
CMP | Compliance Officer | - | 31/03/84 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ryoichi Nagata
CEO | Chief Executive Officer | 65 | 31/08/81 |
Ichiro Nagata
BRD | Director/Board Member | 38 | 31/03/17 |
Sales & Marketing | 64 | 31/10/02 |
Date | Price | Change |
---|---|---|
28/05/24 | 8 | +3.23% |
27/05/24 | 7.75 | +4.03% |
24/05/24 | 7.45 | -2.61% |
23/05/24 | 7.65 | +2.00% |
22/05/24 | 7.5 | -3.23% |
Delayed Quote Deutsche Boerse AG, May 28, 2024 at 07:04 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |
- Stock Market
- Equities
- 2395 Stock
- YB3 Stock